Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study

被引：0

作者：

Ledermann, J. A. ^{[1
,2
]}

Shapira-Frommer, R. ^{[3
]}

Santin, A. ^{[4
]}

Lisyanskaya, A. S. ^{[5
]}

Pignata, S. ^{[6
]}

Vergote, I. ^{[7
]}

Raspagliesi, F. ^{[8
]}

Sonke, G. S. ^{[9
]}

Birrer, M. J. ^{[10
]}

Provencher, D. M. ^{[11
]}

Sehouli, J. ^{[12
]}

Colombo, N. ^{[13
,14
]}

Gonzalez-Martin, A. ^{[15
]}

Oaknin, A. ^{[16
]}

Ottevanger, P. B. ^{[17
]}

Rudaitis, V. ^{[18
]}

Cristescu, R. ^{[19
]}

Kobie, J. ^{[19
]}

Ruman, J. ^{[19
]}

Matulonis, U. A. ^{[20
]}

机构：

[1] UCL, CRUK, London, England

[2] UCL, UCL Canc Inst, UCL Canc Trials Ctr, London, England

[3] Sheba Med Ctr, Med Oncol, Ramat Gan, Israel

[4] Yale Sch Med, Gynecol Oncol, New Haven, CT USA

[5] St Petersburg City Oncol Hosp, Oncogynaecol, St Petersburg, Russia

[6] Ist Nazl Tumori Napoli, Dipartimento Uroginecol, Naples, Italy

[7] Univ Hosp Leuven, Obstet & Gynecol & Gynecol Oncol, Leuven, Belgium

[8] Fdn IRCCS Ist Nazl Tumori Milan, Surg, Milan, Italy

[9] Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands

[10] Univ Alabama Birmingham, Hematol & Oncol, Birmingham, AL USA

[11] Ctr Hosp Univ Montreal, Med Oncol, Montreal, PQ, Canada

[12] Charite Med Univ Berlin, Med Oncol, Berlin, Germany

[13] Univ Milano Bicocca, Gynecol Oncol, Milan, Italy

[14] IRCCS Milan, European Inst Oncol, Milan, Italy

[15] Clin Univ Navarra, Med Oncol, Madrid, Spain

[16] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Oncol, Barcelona, Spain

[17] Radboud Univ Nijmegen, Med Ctr, Med Oncol, Nijmegen, Netherlands

[18] Vilnius Univ, Fac Med, Inst Clin Med, Vilnius, Lithuania

[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA

[20] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA36

引用

页码：728 / 728

页数：1

共 50 条

[21] KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma
Carlino, Matteo
Ribas, Antoni
Gonzalez, Rene
Hoeller, Christoph
Bar-Sela, Gil
Barrow, Catherine
Chao, David
Wolter, Pascal
Berking, Carole
Straume, Oddbjorn
Berrocal, Alfonso
Holgado, Esther
Gangadhar, Tara C.
Weiss, Geoffrey
Zhou, Honghong
Emancipator, Kenneth
Ibrahim, Nageatte
Schadendorf, Dirk
CANCER RESEARCH, 2016, 76
[22] The prevalence of PD-L1 expression in patients with advanced oesophageal cancer: the EXCEED observational study
Xue, Liyan
Wang, Jiaqi
Kuang, Dong
Yun, Jingping
Li, Yuan
Jiang, Lili
Wu, Daoyuan
Duan, Pei
Lu, Shixun
Jin, Yan
He, Du
Qian, Jing
Tang, Wenmin
Wang, Yan
Li, Jielin
Ying, Jianming
JOURNAL OF CLINICAL PATHOLOGY, 2025,
[23] Association of PD-L1 expression with survival benefit from PD-1/PD-L1 inhibitors in advanced cancer: Systematic review and meta-analysis of phase III randomized clinical trials
Kuang, Xiaohong
Xu, Run
Li, Jian
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 198
[24] Phase III Study KEYNOTE-181: Pembrolizumab (KEYTRUDA®) Monotherapy for the Second-line Treatment of advanced Esophageal Cancer or Cancer of the esophagogastral Junction with PD-L1 Expression (CPS ≥ 10)
VISCERAL MEDICINE, 2019, 35 (06) : 396 - 396
[25] Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications
Zhixue Zheng
Zhaode Bu
Xijuan Liu
Lianhai Zhang
Ziyu Li
Aiwen Wu
Xiaojiang Wu
Xiaojing Cheng
Xiaofang Xing
Hong Du
Xiaohong Wang
Ying Hu
Jiafu Ji
Chinese Journal of Cancer Research, 2014, 26 (01) : 104 - 111
[26] Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications
Zheng, Zhixue
Bu, Zhaode
Liu, Xijuan
Zhang, Lianhai
Li, Ziyu
Wu, Aiwen
Wu, Xiaojiang
Cheng, Xiaojing
Xing, Xiaofang
Du, Hong
Wang, Xiaohong
Hu, Ying
Ji, Jiafu
CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (01) : 104 - 111
[27] Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response
Mann, Elise K.
Lee, Kevin J.
Chen, Dongquan
da Silva, Luciana Madeira
Dal Zotto, Valeria L.
Scalici, Jennifer
Gassman, Natalie R.
BIOLOGY-BASEL, 2021, 10 (05):
[28] Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer
Hogdall, Estrid
Hogdall, Claus
Vo, Thao
Zhou, Wei
Huang, Lingkang
Marton, Matthew
Keefe, Stephen M.
Busch-Sorensen, Michael
Sorensen, Sarah M.
Georgsen, Jeanette
Mejlgaard, Else
Nedergaard, Lotte
Steiniche, Torben
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (07) : 1034 - 1042
[29] KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
Daud, Adil
Blank, Christian U.
Robert, Caroline
Puzanov, Igor
Richtig, Erika
Margolin, Kim Allyson
O'Day, Steven
Nyakas, Marta
Lutzky, Jose
Tarhini, Ahmad A.
McWhirter, Elaine
Caglevic, Christian
Mohr, Peter
Millward, Michael
Butler, Marcus O.
Zhou, Honghong
Emancipator, Kenneth
Ebbinghaus, Scot
Ibrahim, Nageatte
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[30] Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study
Ribas, Antoni
Robert, Caroline
Schachter, Jacob
Long, Georgina V.
Arance, Ana
Carlino, Matteo S.
Larkin, James
Webber, Andrea L.
Lunceford, Jared
Zhao, Qing
Cristescu, Razvan
Nebozhyn, Michael
Zhang, Chunsheng
Blumenschein, Wendy
Krepler, Clemens
Ibrahim, Nageatte
Daud, Adil
Grob, Jean-Jacques
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →